Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision genetic medicines for the treatment of severe diseases caused by haploinsufficiency, a condition in which a single functional copy of a gene does not produce enough protein for normal function. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on neurological and genetic disorders. Its core technology platform is based on antisense oligonucleotides designed to selectively increase expression of healthy genes rather than suppress them.
The company’s lead product candidate, zorevunersen, targets mutations in the SCN1A gene and is being developed for Dravet syndrome, a rare and severe genetic epilepsy. Stoke Therapeutics was founded in 2017, emerging from research conducted at Cold Spring Harbor Laboratory, and completed its initial public offering in 2019. Since inception, the company has remained focused on advancing a pipeline of RNA-based medicines addressing unmet medical needs in rare diseases.
Business Operations
Stoke Therapeutics operates as a single-reportable-segment company focused on research and development. Its business activities are centered on the discovery, preclinical development, and clinical testing of antisense oligonucleotide therapies, with no commercial products currently generating revenue. The company’s operations are primarily funded through equity financing and cash reserves, as disclosed in its SEC filings.
The company’s proprietary platform enables targeted upregulation of protein expression from healthy gene alleles. Stoke Therapeutics conducts its research and development internally while leveraging third-party contract research organizations for clinical trials and manufacturing. As of the most recent public disclosures, the company does not report any material revenue from partnerships, product sales, or licensing agreements. Data on additional subsidiaries or joint ventures is inconclusive based on available public sources.
Strategic Position & Investments
Stoke Therapeutics’ strategic direction is centered on advancing zorevunersen through clinical development while expanding its pipeline of antisense-based therapies targeting other haploinsufficiency-driven neurological disorders. A key strategic milestone was the resolution of a prior U.S. Food and Drug Administration clinical hold on zorevunersen, after which the company resumed clinical development under revised trial protocols.
The company has not announced any major acquisitions or equity investments in external portfolio companies. Its investment focus remains internal, prioritizing platform development, clinical trial execution, and regulatory engagement. While management has indicated interest in expanding applications of its core technology, involvement in additional emerging sectors or formal strategic partnerships has not been conclusively verified in public disclosures.
Geographic Footprint
Stoke Therapeutics is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operations are primarily U.S.-based, including research, corporate management, and clinical development activities.
Although headquartered domestically, the company’s clinical trials and regulatory strategy extend its operational influence internationally, including trial sites outside the United States. However, Stoke Therapeutics does not maintain significant physical operations, manufacturing facilities, or regional headquarters outside North America, based on publicly available information.
Leadership & Governance
Stoke Therapeutics was founded by scientists with deep expertise in RNA biology, including Adrian Krainer, whose academic work underpins the company’s technology approach. The leadership team emphasizes a science-driven strategy focused on rigorous clinical validation and disciplined capital allocation.
Key executives include:
- Thomas DiCicco – Chief Executive Officer
- Stephen Fuller – Chief Financial Officer
- Edward M. Kaye – Former Chief Executive Officer and current Board member
- Barry Ticho – Chief Medical Officer
The leadership’s stated strategic vision centers on translating genetic science into transformative therapies for patients with severe rare diseases, while maintaining compliance with regulatory standards and long-term shareholder value creation.